IMU Insider Trading (Imugene)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$630,000.00
Insider Selling (Last 12 Months): A$4,123,782.26
Imugene Share Price & Price History
Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.
But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
Imugene Insider Trading History
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|5/28/2021||Leslie (Mi Ok) Chong||Insider||Exercise||13,844,444||A$0.05||A$622,999.98|
|5/25/2021||Leslie (Mi Ok) Chong||Insider||Sell||4,485,889||A$0.37||A$1,646,321.26|
The Incredible Dividend Map... Where Stocks Yield 26% a Year!
What’s the highest-yielding stock you’ve ever owned?
The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!
When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.
SEC Filings (Institutional Ownership Changes) for Imugene (ASX:IMU)
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
50 Day Range
52 Week Range
Who are the company insiders with the largest holdings of Imugene?
Imugene's top insider investors include:
Learn More about top insider investors at Imugene.
- Axel Hoos (Insider)
- Charles Walker (Insider)
- Jens Eckstein (Insider)
- Lesley Russell (Insider)
- Leslie (Mi Ok) Chong (Insider)
- Leslie Chong (Insider)
- Paul Hopper (Insider)